Glenmark wins regulatory nod to market diabetes drug under brand names Remo-M, Remozen-M in India

Glenmark Pharma will commercialise the combination of Remogliflozin etabonate and Metformin hydrochloride film-coated tablets in India under the brand names 'Remo-M' and 'Remozen-M'.

New Delhi: Glenmark Pharmaceuticals on Monday said it has received regulatory approval to market a combination of Remogliflozin etabonate and Metformin hydrochloride film-coated tablets in India. The drug is indicated for the treatment of type-2 diabetes mellitus in adults, Glenmark said in a statement.

The approved dosage strengths are 100 mg of Remogliflozin combined with either 500 mg or 1,000 mg of Metformin, it added.

Read Also: Torrent Pharma, Glenmark enter an agreement to market Remogliflozin under trademark Zucator in India

"The approval for Remogliflozin and Metformin combination is a testament of our commitment towards revolutionizing diabetes management in India," Glenmark Pharma President India Formulations, Middle East and Africa Sujesh Vasudevan said.

Read Also: Glenmark Pharma misses estimate; records profit of Rs 109.28 crore for June quarter

This combination is indicated as an adjunct to diet and exercise to improve glycemic control in type-2 diabetes mellitus patients, the statement said.

The company will commercialise the product under the brand names 'Remo-M' and 'Remozen-M', it added.

Glenmark Pharma has 16 manufacturing facilities across five countries and has six R&D centres. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

Read Also: USFDA approves Glenmark Pharma anti-anginal drug Ranolazine ER Tablets